NCT05573373View on ClinicalTrials.gov

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 30, 2025

Conditions
Carcinoma, Non-Small-Cell LungEGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG

Parimparib

The dosage and protocol of the drug were carried out according to the description.

DRUG

Chemotherapy drug

The dosage and protocol of the drug were carried out according to the description.

DRUG

Targeted Therapy Agent

The dosage and protocol of the drug were carried out according to the description.

Trial Locations (1)

214000

RECRUITING

Affiliated Hospital of Jiangnan University, Wuxi

All Listed Sponsors
lead

Affiliated Hospital of Jiangnan University

OTHER